Aspen to Acquire Remaining Anesthetics Portfolio from AstraZeneca for $766m

Google+ Pinterest LinkedIn Tumblr +

South African pharma-care giant Apsen Group will acquire the remaining rights to a portfolio of anesthetics from AstraZeneca after it agreed to sell its U.S rights to Aspen for $766 million on Thursday.

The deal will See Aspen pay $555 million upfront, with the remaining $211 million spread across performance-related payments.

AstraZeneca had previously sold all of its rights outside the U.S to Aspen in an earlier deal and would focus rather on oncology, cardiovascular and metabolic diseases and respiratory treatments, Reuters reported.

“Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas,” said AstraZeneca executive Mark Mallon.




About Author

Leave A Reply